Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure

Clinical Cardiology

Volumn 36, Issue 11, 2013, Pages 677-682

  Sargento, Luis ^a   Satendra, Milan ^a   Longo, Susana ^a   Lousada, Nuno ^a   Palma Dos Reis, Roberto ^a  

^a Pulido Valente Hospital Lisbon North Hospital Centre   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; IVABRADINE; METOLAZONE; SPIRONOLACTONE;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PROTEIN STABILITY; SINUS RHYTHM; SYSTOLIC HEART FAILURE;

AGED; AMBULATORY CARE; ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84888003677     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22183     Document Type: Article

References (29)

1. Levy R, White P, Stroud W, et al. Studies of blood pressure in Army officers: 4. Transient tachycardia-prognostic significance alone and in association with transient hypertension. JAMA. 1945; 129: 585-588.
2. Wilhelmsen L, Berglund G, Elmfeldt D, et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J. 1986; 7: 279-288.
3. Cooney MT, Vartiainen E, Laakitainen T, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010; 159: 612-619.
4. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376: 886-894.
5. Hoke RS, Muller-Werdan U, Lautenschlager C, et al. Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol. 2012; 101: 139-147.
6. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010; 16: 475-539.
7. Troughton RW, Richards AM, Yandle TG, et al. The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med. 2007; 39: 242-260.
8. Rosenberg J, Gustafsson F, Remme WJ, et al. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther. 2008; 22: 305-311.
9. White M, Rouleau JL, Afzal R, et al. Effects of enalapril, candersartran or both on neurohormonal activation and LV volumes and function in patients with heart failure not treated with beta-blocker. Ther Adv Cardiovasc Dis. 2009; 3: 113-121.
10. Berry C, Murphy NF, De Vito G, et al. Effects of aldosterone receptor blockage in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail. 2007; 9: 429-434.
11. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004; 110: 1780-1786.
12. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Vaal-HeFT (Valsartran Heart Failure Trial). J Am Coll Cardiol. 2008; 52: 997-1003.
13. Swedberg K, Komadja M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010; 376: 875-885.
14. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011; 32: 2395-2404.
15. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (The CARVIVA HF trial). Int J Cardiol. 2011; 151: 218-224.
16. Tardif JC, O'Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011; 32: 2507-2515.
17. Ceconi C, Freedman SB, tardif JC, et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2010; 146: 408-414.
18. Sarullo FM, Fazio G, Puccio D, et al. Impact of "off label" use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc and Therapeut. 2010; 15: 349-355.
19. Mann DL, Bristow MR,. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111: 2837-2849.
20. Bristow MR,. Adrenergic receptor blockade in chronic heart failure. Circulation. 2000; 101: 558-569.
21. Castagno D, Skali H, Takeuchi M, et al. CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure. J Am Coll Cardiol. 2012; 59: 1785-1795.
22. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Inter Med. 2009; 150: 784-794.
23. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009; 54: 1747-1762.
24. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004; 109: 1674-1679.
25. European Medicines Agency. Committee for Medicinal Products for Human Use. EMA/194513/2012. Assessment report of Pocoralan. Procedure no.: EMEA/H/C/000597/II/0018. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Assessment-Report-Variation/human/000597/WC500124542.pdf. Accessed February 27, 2013.
26. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10: 824-839.
27. Schou M, Gustafsson F, Kjaer A, et al. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J. 2007; 28: 177-182.
28. Schou M, Gustafsson F, Nielsen PH, et al. Unexplained week-to-week variation in BNP and NTproBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail. 2007; 9: 68-74.
29. f inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012; 59: 1938-1945.